Description

With the highest attending rate of academics, TTOs and research institutes, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming from public research institutions, academic spin-offs and emerging biotech companies. Together with big pharma, biotech and diagnostics companies, BioFIT operates as a platform to build partnerships for all public and private actors. BioFIT is also the marketplace for seed investment with cutting-edge technologies.

The 5th edition of BioFIT will gather 1,300 participants (pharma, biotech, IVD companies, TTOs, academia and investors) from 30+ countries, who will meet to discuss new partnerships, facilitate the emergence of collaborative projects and increase licensing opportunities in Life Sciences. Indeed, BioFIT has emerged as the leading event in Europe for academia-industry collaborations and for sourcing early-stage innovations stemming from both public research institutions and academic spin-offs.

Many key players have already confirmed their presence, including Pfizer, J&J, Sanofi, Takeda, Roche, GSK, Novo Nordisk, AstraZeneca, Lilly, Bayer, Merck, Novartis, Karo Bio, Janssen Pharmaceutica, Evotec, Lonza, Astellas Ventures, Ipsen Innovation, Boehringer Ingelheim, Genfit, Sofinnova Partners, Karolinska Development, Kurma Partners, AmorChem, Index Ventures, Max Planck Institute, MRC Technology, Provendis…

Leading actors in Diabetes, Oncology and Innovative services will also join BioFIT for 2 days of intensive partnering and networking. Check out the the list of the 2016 participants on the event’s website.

This international event combines:

Click here to register for the event : http://www.biofit-event.com/registration/registration-fees

Contact :

Margaux Satola Business Development manager[email protected]PHONE: +33 (0) 359 390 182

Cluster organisation
Share this Article